Macrocyclic CD8 Capture Agents for Sensitive T-Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for sensitive and selective tools for detecting CD8+ T cells, which are crucial for immunotherapy in cancer treatment, as they can recognize tumor-associated antigens and kill tumor cells, but existing methods lack the necessary specificity and sensitivity.
Innovation Solution
Development of epitope-targeted macrocyclic peptide ligands and capture agents that bind specifically to CD8, utilizing synthetic epitopes reminiscent of monoclonal antibodies, formed by in situ click screening of one-bead-one-compound peptide libraries, with cyclic peptides displaying enhanced bioavailability and stability, and a linker connecting two ligands to enhance binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing detection methods are used for CD8+ T cells, then the detection process is simpler, but the sensitivity and specificity are insufficient
Solution Approach 1:
The patent changes the chemical parameters of the detection agent by using cyclic peptide ligands with specific amino acid sequences instead of traditional antibodies. These peptide ligands have modified chemical structures that provide enhanced binding characteristics to CD8, improving detection sensitivity and specificity while maintaining practical usability in immunotherapy monitoring
Solution Approach 2:
The patent employs composite detection agents consisting of cyclic peptide ligands combined with detection labels or fluorescent tags. This composite structure integrates the high specificity of peptide-CD8 binding with the detectability of attached markers, achieving both improved measurement precision and maintained ease of operation through standardized assay protocols
2Reliability
If cyclic peptide ligands are used instead of linear peptides, then binding affinity and stability are enhanced, but synthesis and purification become more complex
Solution Approach 1:
The patent applies preliminary protective group strategies during peptide synthesis to facilitate cyclic structure formation. By pre-installing appropriate functional groups at specific positions before cyclization, the synthesis process becomes more controlled and efficient, reducing purification complexity while ensuring high binding stability of the final cyclic peptide product
Solution Approach 2:
The patent replaces traditional mechanical purification methods with chemical selection strategies. The cyclic peptide ligands are designed with specific chemical properties that allow selective binding to CD8 targets, enabling affinity-based purification that is more efficient than conventional chromatographic methods, thus improving reliability while managing manufacturing complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The capture agents provide stable and selective binding to CD8, enabling sensitive detection and quantification of CD8+ T cells, improving immunotherapy by allowing for patient stratification and monitoring treatment responses.
Implementation Method 1
a first ligand having affinity for a first epitope on CD8, a second ligand having affinity for a second epitope on CD8
Data Source
AI summary
The present application provides stable peptide-based CD8 capture agents and methods of use as detection agents. The application further provides methods of manufacturing CD8 capture agents.